NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Quantum BioPharma's Lucid-MS Toxicity Studies and Company Overview
TL;DR
Quantum BioPharma's completion of oral dosing studies for Lucid-MS positions it ahead in developing a first-in-class MS treatment, potentially offering investors early advantage in a promising biotech sector.
Quantum BioPharma completed 180-day chronic toxicity and toxicokinetic studies for Lucid-MS, supporting its IND application with the FDA and advancing toward Phase 2 clinical trials for multiple sclerosis.
This milestone brings Quantum BioPharma's Lucid-MS closer to clinical trials, potentially offering new hope for people with multiple sclerosis by addressing the underlying mechanism of myelin degradation.
Quantum BioPharma's Lucid-MS is a patented compound shown to prevent and reverse myelin degradation in preclinical models, representing a novel approach to treating multiple sclerosis.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma has completed oral dosing in both 180-day chronic toxicity and toxicokinetic studies for its drug candidate Lucid-MS (Lucid-21-302).
This milestone supports the company's planned Investigational New Drug application with the U.S. Food and Drug Administration and moves the program closer to clinical-stage development for this first-in-class therapeutic candidate.
Lucid-MS is Quantum BioPharma's patented new chemical entity designed to treat multiple sclerosis by preventing and reversing myelin degradation, which is the underlying mechanism of the disease.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for treating challenging neurodegenerative and metabolic disorders and alcohol misuse disorders.
unbuzzd™ is a product invented by Quantum BioPharma that was spun out to Unbuzzd Wellness Inc.; Quantum BioPharma retains 20.11% ownership and receives royalty payments of 7% of sales until payments total $250 million, then 3% in perpetuity.
The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
The studies support the design and advancement of a Phase 2 clinical trial of Lucid-MS in people with multiple sclerosis.
Through its wholly owned subsidiary FSD Strategic Investments Inc., Quantum BioPharma maintains a portfolio of strategic investments representing loans secured by residential or commercial property.
Curated from InvestorBrandNetwork (IBN)
